• Embrace (A): Opportunity Identification

    <p style="color: rgb(197, 183, 131);"><strong> AWARD WINNER - Indian Management Issues and Opportunities Award, European Foundation for Management Development (EFMD) Case Writing Competition</strong></p><br>The Embrace case series provides an engaging context to understand social innovation, by taking students through a sequence of critical decisions from opportunity analysis and market feasibility study to formulating a competitive strategy and developing business models for growth. The focus of the case is on an innovative idea to solve the problem of a high number of fatalities in premature births in rural India, and the potential for an affordable product. <br><br><br><br>The case is structured as a four-part series:<ul><li><br>Part A: Opportunity Identification. The setting is an MBA classroom where five teams have been given five ideas and the students are asked to match each idea to each team. The focus is on how to identify and evaluate an appropriate opportunity given a unique entrepreneurial team, its composition, and its prior experience. Often, entrepreneurs discount the critical role that team-task fit plays in subsequent success.</li><li><br>Part B: Market Feasibility Analysis (9B13M005). The social problem associated with neonatal care in rural India is presented and the economics of providing reasonable care for premature babies is discussed. Is it possible to find an affordable and profitable price point, and make the project sustainable?</li><li><br>Part C: Competitive Strategy (9B13M006). The students are taken through an external analysis of the potential competition. This calls for a close analysis of what the competitive advantage of the venture is and whether it is sustainable. It forces the students to consider other available neonatal care options in the market, as well as to think about the IP issues they could face.</li><li><br>Part D: Building the Business Model (9B13M007). The team must decide between manufacturing the product in-house or outsourcing to vendors. Also, issues of distribution and sales require consideration.</li></ul>
    詳細資料
  • Embrace (B): Opportunity Assessment

    <p style="color: rgb(197, 183, 131);"><strong> AWARD WINNER - Indian Management Issues and Opportunities Award, European Foundation for Management Development (EFMD) Case Writing Competition</strong></p><br>Part B of a four-part series, which also includes 9B13M004, 9B13M006 and 9B13M007.
    詳細資料
  • Embrace (C): Competing with Incumbents

    <p style="color: rgb(197, 183, 131);"><strong> AWARD WINNER - Indian Management Issues and Opportunities Award, European Foundation for Management Development (EFMD) Case Writing Competition</strong></p><br>Part C of a four-part series, which also includes 9B13M004, 9B13M005 and 9B13M007.
    詳細資料
  • Embrace (D): Building the Business Model

    <p style="color: rgb(197, 183, 131);"><strong> AWARD WINNER - Indian Management Issues and Opportunities Award, European Foundation for Management Development (EFMD) Case Writing Competition</strong></p><br>Part D of a four-part series, which also includes 9B13M004, 9B13M005 and 9B13M006.
    詳細資料
  • Novartis in India: Innovation versus Affordability - PowerPoint Presentation

    PowerPoint presentation for product 8B12M111.
    詳細資料
  • Novartis in India: Innovation versus Affordability

    This case presents complex managerial challenges that stem from the institutional context in emerging markets, particularly in relation to the intellectual property regime and its impact on business strategy. The case centres around a multinational pharmaceutical firm, Novartis International AG (Novartis), that is waiting on a major court decision regarding patent policy as it pertains to one of the firm’s products. <br><br><br><br>The case takes students through the company’s journey in marketing a promising anti-cancer drug that had global sales of US$3.9 billion in 2009. Novartis’ global success with this drug is being challenged by the changing institutional environment surrounding innovation and pharmaceutical patents. The company’s decision to patent the drug in India and challenge the institutional system of patent law is meeting significant resistance from those who argue that the drug is neither novel nor affordable for most patients. With key domestic players staking their claim to the large pool of patients who could benefit from the drug, the case focuses on a controversial patents law. Given the uncertainty of the court’s final decision on these matters, students are asked to develop an action plan for the company’s future.
    詳細資料